| Name | CYP2A13 |
|---|---|
| Synonyms | CPAD; CYP2A; CYP2A13; CYPIIA13; Cytochrome P450 2A13; Cytochrome P450 2A13 variant 5; Cytochrome P450 2A13 variant 6; Cytochrome P450 2A13s… |
| Name | nicotine |
|---|---|
| CAS |
| PubMed | Abstract | RScore(About this table) | |
|---|---|---|---|
| 19434638 | Chougnet A, Woggon WD, Locher E, Schilling B: Synthesis and in vitro activity of heterocyclic inhibitors of CYP2A6 and CYP2A13, two cytochrome P450 enzymes present in the respiratory tract. Chembiochem. 2009 Jun 15;10(9):1562-7. These compounds were tested as inhibitors of CYP2A6 and CYP2A13--two cytochrome P450 enzymes present in the respiratory tract--with a view to preventing the formation of carcinogenic metabolites of nicotine and inhibiting the metabolism of fragrances. 1-Substituted imidazoles bearing short alkyl chains displayed IC (50) values of around 2 microM for both enzymes, together with high vapour pressures. |
32(0,1,1,2) | Details |
| 19251817 | DeVore NM, Smith BD, Wang JL, Lushington GH, Scott EE: Key residues controlling binding of diverse ligands to human cytochrome P450 2A enzymes. Drug Metab Dispos. 2009 Jun;37(6):1319-27. Epub 2009 Feb 27. Although the human lung cytochrome P450 2A13 (CYP2A13) and its liver counterpart cytochrome P450 2A6 (CYP2A6) are 94% identical in amino acid sequence, they metabolize a number of substrates with substantially different efficiencies. To determine differences in binding for a diverse set of cytochrome P450 2A ligands, we have measured the spectral binding affinities (K (D)) for nicotine, phenethyl isothiocyanate (PEITC), 2'-methoxyacetophenone (MAP), and 8-methoxypsoralen. |
5(0,0,0,5) | Details |
| 19018727 | Rossini A, de Almeida Simao T, Albano RM, Pinto LF: CYP2A6 polymorphisms and risk for tobacco-related cancers. Pharmacogenomics. 2008 Nov;9(11):1737-52. The psychoactive compound responsible for tobacco addiction, nicotine and the potent carcinogens present at high concentrations either in cigarette mainstream smoke or in smokeless tobacco products, 4-(methylnitrosamino)-1-(3-pyridyl)- (NNK) and N-nitrosonornicotine (NNN) can be metabolized by CYP2A6. The overlapping substrate specificity and tissue expression between CYP2A6 and the highly similar CYP2A13 may add to the conflicting results observed. |
3(0,0,0,3) | Details |
| 19923441 | Zhou X, Zhuo X, Xie F, Kluetzman K, Shu YZ, Humphreys WG, Ding X: Role of CYP2A5 in the clearance of nicotine and insights from studies on a Cyp2a5-null mouse model. J Pharmacol Exp Ther. 2010 Feb;332(2):578-87. Epub 2009 Nov 18. CYP2A5, a mouse cytochrome P450 monooxygenase that shows high similarities to human CYP2A6 and CYP2A13 in protein sequence and substrate specificity, is expressed in multiple tissues, including the liver, kidney, lung, and nasal mucosa. |
2(0,0,0,2) | Details |
| 19996203 | Tan XL, Wang T, Xiong S, Kumar SV, Han W, Spivack SD: Smoking-Related Gene Expression in Laser Capture-Microdissected Human Lung. Clin Cancer Res. 2009 Dec 15;15(24):7562-7570. Epub . EXPERIMENTAL DESIGN: Tobacco exposure was determined by plasma nicotine, and smoking history. |
0(0,0,0,0) | Details |